+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Implementation of Global Strategies to Prevent Hospital-Onset Clostridium difficile Infection: Targeting Proton Pump Inhibitors and Probiotics



Implementation of Global Strategies to Prevent Hospital-Onset Clostridium difficile Infection: Targeting Proton Pump Inhibitors and Probiotics



Annals of PharmacoTherapy 51(10): 848-854



Proton pump inhibitors (PPIs) have been identified as a significant risk factor for the development of Clostridium difficile infection (CDI). Probiotics given concurrently with antibiotics have been shown to have a moderate impact on preventing CDI. To evaluate the effectiveness of hospital-wide interventions designed to reduce PPI use and increase probiotics and whether these interventions were associated with a change in the incidence of hospital onset (HO)-CDI. This retrospective cohort study compared 2 fiscal years: July 2013 to June 2014 (FY14) and July 2014 to June 2015 (FY15). In July of FY15, global educational initiatives were launched targeting PPIs. Additionally, a HO-CDI prevention bundle was added to antibiotic-containing order sets targeting probiotics. Overall PPI use, probiotic use, and incidence of HO-CDI were recorded and compared for each cohort. Charts were also reviewed for patients who developed HO-CDI for the presence and appropriateness of a PPI and presence of probiotics. The interventions resulted in a decrease in PPI use by 14% or 96 doses/1000 patient days (TPD; P = 0.0002) and a reduction in IV PPI use by 31% or 71 doses/TPD ( P = 0.0008). Probiotic use increased by 130% or 126 doses/TPD ( P = 0.0006). The incidence of HO-CDI decreased by 20% or 0.1 cases/TPD ( P = 0.04). A collaborative, multifaceted educational initiative directed at highlighting the risks associated with PPI use was effective in reducing PPI prescribing. The implementation of a probiotic bundle added to antibiotic order sets was effective in increasing probiotic use. These interventions were associated with a decrease in incidence of HO-CDI.

(PDF emailed within 0-6 h: $19.90)

Accession: 059841164

Download citation: RISBibTeXText

PMID: 28821215

DOI: 10.1177/1060028017694050


Related references

Proton Pump Inhibitors Should be Used with Caution in Critically Ill Patients to Prevent the Risk of Clostridium difficile Infection. Gut and Liver 10(4): 493-494, 2016

Proton Pump Inhibitors and the Risk for Hospital-Acquired Clostridium difficile Infection. Mayo Clinic Proceedings 88(10): 1085-1090, 2013

Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients. Critical Care 18(6): 714-714, 2015

Risk and Severity of Hospital-Acquired Clostridium difficile Infection in Patients Taking Proton Pump Inhibitors. PharmacoTherapy 36(9): 986-993, 2016

Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting. Alimentary Pharmacology & Therapeutics 29(6): 626-634, 2009

PTH-027Stopping Proton Pump Inhibitors to Prevent Clostridium Difficile: Is it Possible and Does it Help?. Gut 62(Suppl 1): A222.2-A222, 2013

Proton pump inhibitors are an independent risk factor for an increased length of hospital stay in patients with Clostridium difficile infection. Indian Journal of Gastroenterology 27(4): 171-172, 2008

Withholding Proton Pump Inhibitors to Prevent Recurrent Clostridium difficile: Time for a Randomized Trial. JAMA Internal Medicine 177(6): 791-791, 2017

Clostridium difficile infection and proton pump inhibitors. Current Opinion in Pediatrics 24(5): 627-631, 2013

Proton pump inhibitors and the risk for Clostridium difficile infection. JAMA 302(1): 31-2; Author Reply 32, 2009

Clostridium difficile infection is associated with proton pump inhibitors in patients with cirrhosis. 2007

Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Archives of Internal Medicine 170(9): 772-778, 2010

Proton-pump inhibitors are associated with increased risk for Clostridium difficile infection. 2012

Clostridium difficile infection in the community: are proton pump inhibitors to blame?. World Journal of Gastroenterology 19(40): 6710-6713, 2014

Proton pump inhibitors and risk of Clostridium difficile infection: association or causation?. Current Opinion in Gastroenterology, 2017